Oppenheimer & Co. Inc. Has $404,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Oppenheimer & Co. Inc. cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,716 shares of the biopharmaceutical company’s stock after selling 190 shares during the period. Oppenheimer & Co. Inc.’s holdings in Alnylam Pharmaceuticals were worth $404,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $42,000. Finally, True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,986 shares of company stock worth $20,397,849 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Finally, HC Wainwright raised their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $304.26.

Alnylam Pharmaceuticals Stock Down 1.5 %

NASDAQ:ALNY opened at $244.52 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm’s 50 day simple moving average is $254.57 and its 200 day simple moving average is $261.71. The company has a market cap of $31.65 billion, a PE ratio of -112.68 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.